Corcept Therapeutics (CORT) Superinvestor holders
12 of the superinvestors we track hold Corcept Therapeutics (CORT) in their latest 13F filings, $869M in total.
Summary
The largest holder is Jim Simons (Renaissance Technologies), with $457M, 0.6% of the portfolio.
In their latest quarter: 4 added, 7 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Jim Simons Renaissance Technologies |
Trimmed | 5,261,628 | $457M | 0.6% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | 2,582,561 | $225M | 0.1% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 883,001 | $77M | 0.1% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 610,078 | $53M | 0.0% | Q2 2026 |
| Chuck Royce Royce Investment Partners |
Trimmed | 132,800 | $15M | 0.1% | Q3 2026 |
| Acadian Acadian Asset Management |
Added | 125,481 | $14M | 0.0% | Q3 2026 |
| Eddie Brown Brown Capital Management |
Held | 84,041 | $10M | 1.8% | Q3 2026 |
| Man Group Man Group plc |
Trimmed | 71,491 | $6M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Added | 60,181 | $5M | 0.0% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Added | 57,602 | $5M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
Trimmed | 5,628 | $489,354 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Trimmed | 5,089 | $442,489 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 12 |
| Q1 2026 | 17 |
| Q4 2025 | 16 |
| Q3 2025 | 17 |
| Q2 2025 | 15 |
| Q1 2025 | 14 |
| Q4 2024 | 16 |
| Q3 2024 | 14 |
Questions about Corcept Therapeutics
Which superinvestors own Corcept Therapeutics?
12 of the superinvestors we track hold Corcept Therapeutics (CORT) in their latest 13F filings, $869M in total. Jim Simons, Cliff Asness, David Shaw, Two Sigma, Chuck Royce, Acadian.
Who is the largest superinvestor holder of CORT?
The largest holder is Jim Simons (Renaissance Technologies), with $457M, 0.6% of the portfolio.
From Corcept Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.